ストックスクリーナーアプリを入手
34.22
2.06%
-0.72
Rigel Pharmaceuticals (RIGL) 最新ニュース
Rigel Pharmaceuticals Charts Course Toward Profitability - AD HOC NEWS
Piper Sandler Maintains Rigel Pharmaceuticals(RIGL.US) With Hold Rating, Raises Target Price to $42 - 富途牛牛
Understanding the Setup: (RIGL) and Scalable Risk - Stock Traders Daily
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Beacon Harbor Wealth Advisors Inc. Makes New $4.31 Million Investment in Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
Rigel Pharmaceuticals Appoints Michael P. Miller to Board - The Globe and Mail
Rigel Pharmaceuticals, Inc. Appoints Michael P. Miller to Its Board of Directors - marketscreener.com
Rigel Appoints Michael P. Miller to the Board of Directors - ChartMill
Rigel Pharmaceuticals Appoints New Board Member - Intellectia AI
Rigel Pharmaceuticals sees Q4 revenue $57.6M, consensus $47.42M - TipRanks
Rigel Pharmaceuticals (NASDAQ:RIGL) Stock Crosses Above Two Hundred Day Moving AverageHere's Why - MarketBeat
Sanofi keeps mum on future of disappointing Denali pact after scrapping final RIPK1 inhibitor - Fierce Biotech
FOLD vs. RIGL: Which Rare Disease Biotech Stock Has Better Upside? - TradingView
Quarterly Earnings: What are Rigel Pharmaceuticals Incs earnings expectationsJuly 2025 EndofMonth & Long Hold Capital Preservation Plans - baoquankhu1.vn
H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $57 - 富途牛牛
Published on: 2026-01-27 18:41:00 - baoquankhu1.vn
The Technical Signals Behind (RIGL) That Institutions Follow - Stock Traders Daily
Rigel Pharmaceuticals: Continued Financial Performance, Catalysts In 2026 (RIGL) - Seeking Alpha
JW Pharmaceutical shares real-world prescribing data for immune thrombocytopenia drug Tavalisse - koreabiomed.com
JW Pharmaceutical Shares Clinical Results and Prescription Experience of Immune Thrombocytopenia Treatment at ABFS 2026 - 아시아경제
Rigel Pharmaceuticals price target raised to $71 from $69 at Citi - TipRanks
Rigel Pharmaceuticals (NASDAQ:RIGL) Downgraded to "Strong Sell" Rating by Zacks Research - MarketBeat
RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL): A GARP Stock with Affordable Growth and Strong Fundamentals - Chartmill
How The Narrative Around Rigel Pharmaceuticals (RIGL) Is Shifting With Raised Guidance And Cash Flow - Yahoo Finance
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Sees Significant Growth in Short Interest - MarketBeat
Rigel Pharmaceuticals (RIGL) Valuation After New REZLIDHIA Trial And 2026 Revenue Guidance - simplywall.st
Rigel Pharmaceuticals, Inc. (RIGL) Releases Preliminary Results for Q4 2025 - Insider Monkey
Is Rigel Pharmaceuticals (RIGL) 2026 Revenue Guidance Reframing Its Commercial-Led Investment Narrative? - Yahoo Finance
Precision Trading with Rigel Pharmaceuticals Inc. (RIGL) Risk Zones - Stock Traders Daily
New leukemia drug combo enters trial for patients with hard-to-treat AML - Stock Titan
HC Wainwright Has Negative Forecast for RIGL FY2026 Earnings - MarketBeat
10 Best Performing Affordable Stocks Under $40 - Insider Monkey
A Look At Rigel Pharmaceuticals (RIGL) Valuation After Issuing 2026 Revenue Guidance - Yahoo Finance
Equities Analysts Issue Forecasts for RIGL FY2025 Earnings - MarketBeat
Will Rigel Pharmaceuticals Inc stock outperform tech sector in 2025Gap Down & Low Drawdown Trading Strategies - Bộ Nội Vụ
Rigel Pharmaceuticals (RIGL) Is Down 7.7% After Issuing Detailed 2026 Revenue Mix Guidance – Has The Bull Case Changed? - simplywall.st
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Rigel Announces Strong Preliminary 2025 Results and Outlook - TipRanks
Rigel Pharmaceuticals sees FY26 revenue $275M-$290M, consensus $291.58M - TipRanks
Rigel Pharmaceuticals (RIGL) Reports Impressive Financial Results - GuruFocus
Rigel (RIGL) Projects Strong Revenue Growth for 2025 - GuruFocus
Rigel Provides Business Update and 2026 Outlook - marketscreener.com
Why Rigel Pharmaceuticals Inc. stock is popular among millennials2025 Technical Overview & Short-Term Trading Alerts - ulpravda.ru
Rigel Pharmaceuticals (RIGL) Beats Q1 Earnings and Revenue Estimates - sharewise.com
Rigel Pharmaceuticals (NASDAQ:RIGL) Trading Down 5.3%Here's What Happened - MarketBeat
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NA - GuruFocus
Rigel Pharmaceuticals, Inc. announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - StreetInsider
Earnings Risk: Will Rigel Pharmaceuticals Inc. (RI2) stock gain from green policies2025 Price Momentum & Expert Approved Momentum Ideas - Улправда
Is Rigel Pharmaceuticals Inc. stock a buy in volatile markets2025 Major Catalysts & Long-Term Growth Stock Strategies - Улправда
Is Rigel Pharmaceuticals Inc. stock supported by strong cash flows2025 Support & Resistance & Real-Time Sentiment Analysis - ulpravda.ru
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):